Selpercatinib (LOXO-292) in patients with RET-fusion+ non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.3584
Abstract: 3584Background: Selpercatinib (LOXO-292) is a highly selective and potent small molecule RET kinase inhibitor. Here we report an update on the efficacy and safety of selpercatinib in RET-fusion+ no... read more here.
Keywords: selpercatinib loxo; ret fusion; loxo 292; 292 patients ... See more keywords